Tinghu Zhang

This paper develops covalent EGFR inhibitors targeting cysteine 775 and 797, showing improved efficacy and resistance delay in osimertinib-resistant models.

This paper develops KAT-TCIPs to induce cell death in diffuse large B cell lymphoma by redirecting p300 and CBP to activate programmed cell death genes repressed by BCL6.

This paper develops a small molecule, TRAP-1, that activates mutant p53 by forming a ternary complex with BRD4, leading to p53 target gene upregulation and inhibition of cancer cell growth.

This paper identifies a druggable redox switch on SHP1 that controls macrophage inflammation by developing a covalent agonist targeting a specific cysteine residue.

This study identifies a PTER inhibitor that reduces food intake and body weight in mice, linking PTER function to obesity treatment.

This paper introduces DD-CIPs, bivalent molecules that induce DNA damage response and apoptosis in cancer cells, showing efficacy against PARPi-resistant cancers.

This study shows CDK12/13 inhibition disrupts nucleolar structure and causes aberrant IGS rRNA transcript expression due to impaired processing and degradation.

The paper develops bivalent molecules that convert kinase inhibitors into activators of proapoptotic genes, achieving selective killing of DLBCL cells with low cytotoxicity.

This study develops small molecule degraders of the dengue virus envelope protein, demonstrating their ability to induce proteosome-mediated degradation and providing a foundation for antiviral drug development.